IDH2 and acute myeloid leukemia: Furthermore, based on these advances, several drugs have been approved for the treatment of AML, such as sorafenib for FMS-like tyrosine kinase 3 (FLT3) mutations and Evonib for isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations [17].